|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
101,000,000 |
Market
Cap: |
700.94(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.7528 - $16.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 14 |
Insider 6 Months : 14 |
Insider 3/6 Months : 28.4 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
302,064 |
302,064 |
532,064 |
632,064 |
Total Buy Value |
$2,399,132 |
$2,399,132 |
$2,709,632 |
$2,855,122 |
Total People Bought |
1 |
1 |
3 |
4 |
Total Buy Transactions |
3 |
3 |
5 |
6 |
Total Shares Sold |
0 |
0 |
0 |
68,099 |
Total Sell Value |
$0 |
$0 |
$0 |
$57,808 |
Total People Sold |
0 |
0 |
0 |
4 |
Total Sell Transactions |
0 |
0 |
0 |
4 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gasmi Mehdi |
Director |
|
2018-02-12 |
4 |
D |
$6.85 |
$74,021 |
D/D |
(10,806) |
248,367 |
|
- |
|
Gasmi Mehdi |
Director |
|
2018-02-09 |
4 |
D |
$7.05 |
$80,603 |
D/D |
(11,433) |
259,173 |
|
- |
|
Patterson Leone D |
CEO, President and Director |
|
2018-02-09 |
4 |
D |
$7.05 |
$57,866 |
D/D |
(8,208) |
162,397 |
|
- |
|
Carter Eric G |
Director |
|
2017-09-07 |
4 |
A |
$0.00 |
$0 |
D/D |
48,000 |
48,000 |
|
- |
|
Gasmi Mehdi |
Director |
|
2017-08-21 |
4 |
D |
$2.50 |
$13,698 |
D/D |
(5,479) |
270,606 |
|
- |
|
Countouriotis Athena |
SVP, Chief Medical Officer |
|
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
Patterson Leone D |
CEO, President and Director |
|
2017-06-15 |
4 |
D |
$2.70 |
$25,367 |
D/D |
(9,395) |
170,605 |
|
- |
|
Spivey Richard N. |
Director |
|
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
70,804 |
|
- |
|
Finer Mitchell H. |
Director |
|
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
603,069 |
|
- |
|
Woiwode Thomas |
Director |
|
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
70,380 |
|
- |
|
Cleveland Paul B |
Chief Executive Officer |
|
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
22,727 |
|
- |
|
Schwartz Steven Daniel |
Director |
|
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
398,991 |
|
- |
|
Machado Clarence Patrick |
Director |
|
2017-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,727 |
68,182 |
|
- |
|
Woiwode Thomas |
Director |
|
2017-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,223 |
47,653 |
|
- |
|
Gasmi Mehdi |
Director |
|
2017-04-21 |
4 |
D |
$2.70 |
$1,774 |
D/D |
(657) |
276,085 |
|
- |
|
Spivey Richard N. |
Director |
|
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
48,077 |
48,077 |
|
- |
|
Woiwode Thomas |
Director |
|
2017-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,704 |
45,430 |
|
- |
|
Machado Clarence Patrick |
Director |
|
2017-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
45,455 |
45,455 |
|
- |
|
Woiwode Thomas |
Director |
|
2017-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,774 |
41,726 |
|
- |
|
Gasmi Mehdi |
Director |
|
2017-02-12 |
4 |
D |
$3.00 |
$38,379 |
D/D |
(12,793) |
276,742 |
|
- |
|
Salzman Amber |
President and CEO |
|
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
262,000 |
891,766 |
|
- |
|
Patterson Leone D |
CFO |
|
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
180,000 |
|
- |
|
Gasmi Mehdi |
Chief Science & Tech Officer |
|
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
289,535 |
|
- |
|
Barone Samuel B. |
SVP, Clinical Development |
|
2017-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
58,000 |
172,335 |
|
- |
|
Woiwode Thomas |
Director |
|
2016-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,449 |
34,503 |
|
- |
|
266 Records found
|
|
Page 5 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|